MANGOCEUTICALS INC

Company Overview

Mangoceuticals Inc. is a Texas-based telehealth and men’s wellness company in the Healthcare sector and Health Information Services industry. Its business centers on connecting consumers with licensed healthcare professionals through its MangoRX platform and fulfilling prescriptions through a related-party compounding pharmacy, while selling branded men’s health products such as ED, hair-loss, hormone, and weight-loss treatments. The company also markets PRIME, an FDA-approved testosterone replacement therapy, and is pursuing additional intellectual property and product commercialization initiatives. Recent filings show a business in transition, with revenue pressured by platform migration, while management continues to emphasize growth through marketing, product launches, and strategic alternatives.

Executive Compensation Practices

Executive compensation at Mangoceuticals appears to be heavily influenced by equity incentives rather than stable cash operating performance, which is common for smaller healthcare platform companies trying to conserve cash. The filings show a sharp increase in stock-based compensation to $10.8 million in 2025, suggesting that management pay and retention packages are closely tied to share price and equity issuance, not just revenue growth. Compensation drivers likely reflect milestones such as platform migration, product development, intellectual property transactions, financing execution, and expansion of the telehealth and wellness portfolio. Given the company’s ongoing cash burn, recurring losses, and need for outside capital, executives may also be incentivized through warrants, options, or other equity-linked instruments to align with fundraising and strategic transaction goals.

Insider Trading Considerations

Insider trading activity in Mangoceuticals should be viewed in the context of a thinly capitalized healthcare company with frequent financing needs, strategic review activity, and substantial dilution risk. Because the company depends on continued capital raises, warrant exercises, common stock sales, and related-party financing, insider transactions may be especially informative as signals about management’s view of future financing terms and dilution. The company’s reliance on a related-party pharmacy controlled by the CEO, along with ongoing regulatory exposure around telehealth, compounded drugs, and advertising, may also affect trading windows and increase the likelihood of cautious insider behavior around material operational updates. Researchers should pay close attention to insider purchases or sales around financing announcements, product launches, strategic alternatives, and changes in stock-based compensation or equity issuance, since these events are likely to have an outsized effect on valuation and trading sentiment.